Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression.

Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A.

J Natl Cancer Inst. 2014 Apr;106(4):dju043. doi: 10.1093/jnci/dju043. Epub 2014 Mar 13.

2.

Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma.

Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A.

RNA. 2013 Feb;19(2):177-90. doi: 10.1261/rna.036467.112. Epub 2012 Dec 18.

3.

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, Thomas-Tikhonenko A.

Cancer Res. 2011 Dec 15;71(24):7490-501. doi: 10.1158/0008-5472.CAN-11-1124. Epub 2011 Oct 25.

4.

The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma.

Mestdagh P, Boström AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquière B, Schulte S, Dews M, Thomas-Tikhonenko A, Schulte JH, Zollo M, Schramm A, Gevaert K, Axelson H, Speleman F, Vandesompele J.

Mol Cell. 2010 Dec 10;40(5):762-73. doi: 10.1016/j.molcel.2010.11.038.

5.

The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors.

Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A.

Cancer Res. 2010 Oct 15;70(20):8233-46. doi: 10.1158/0008-5472.CAN-10-2412. Epub 2010 Oct 12.

6.

Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis.

Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A.

Adv Cancer Res. 2009;105:115-32. doi: 10.1016/S0065-230X(09)05007-6. Review.

7.

Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.

J Natl Cancer Inst. 2009 May 6;101(9):663-77. doi: 10.1093/jnci/djp063. Epub 2009 Apr 28.

8.

Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation.

Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, Thomas-Tikhonenko A, Mendell JT.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3384-9. doi: 10.1073/pnas.0808300106. Epub 2009 Feb 11.

9.

c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster.

Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang TC, Schelter JM, Cleary MA, Mendell JT, Thomas-Tikhonenko A.

Cancer Biol Ther. 2008 Nov;7(11):1758-64. Epub 2008 Nov 4.

10.

Aiding and ABT'ing Treatment for Glioblastoma.

Chung EY, Dews M, Maity A, Thomas-Tikhonenko A.

Cancer Biol Ther. 2007 May;6(5):802-4. Epub 2007 May 15. No abstract available.

11.

Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.

Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A.

Nat Genet. 2006 Sep;38(9):1060-5. Epub 2006 Jul 30.

12.
13.

Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.

Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS.

Mol Cell Biol. 2004 Oct;24(19):8541-55.

14.

Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo.

Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE.

Cancer Res. 2004 May 1;64(9):3126-36.

15.

The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells.

Morrione A, Navarro M, Romano G, Dews M, Reiss K, Valentinis B, Belletti B, Baserga R.

Oncogene. 2001 Aug 9;20(35):4842-52.

16.

Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras.

Cristofanelli B, Valentinis B, Soddu S, Rizzo MG, Marchetti A, Bossi G, Morena AR, Dews M, Baserga R, Sacchi A.

Oncogene. 2000 Jul 6;19(29):3245-55.

17.

Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells.

Morrione A, Romano G, Navarro M, Reiss K, Valentinis B, Dews M, Eves E, Rosner MR, Baserga R.

Cancer Res. 2000 Apr 15;60(8):2263-72.

18.

Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases.

Dews M, Prisco M, Peruzzi F, Romano G, Morrione A, Baserga R.

Endocrinology. 2000 Apr;141(4):1289-300.

PMID:
10746631
19.

Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.

Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R.

Mol Cell Biol. 1999 Oct;19(10):7203-15.

21.

The IGF-I receptor and cancer.

Baserga R, Resnicoff M, Dews M.

Endocrine. 1997 Aug;7(1):99-102. Review. No abstract available.

PMID:
9449042
22.

IGF-I receptor protection from apoptosis in cells lacking the IRS proteins.

Dews M, Nishimoto I, Baserga R.

Recept Signal Transduct. 1997;7(4):231-40.

PMID:
9633824
23.
24.

Mushroom poisoning. 2. Nursing care.

DEWS MJ.

Am J Nurs. 1956 Aug;56(8):1000. No abstract available.

PMID:
13339844

Supplemental Content

Support Center